Hydroxy-Carboxylic Acid Receptor Actions in Metabolism

Trends in Endocrinology and Metabolism

Volumn 28, Issue 3, 2017, Pages 227-236

  Offermanns, Stefan ^a,b  

^a MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

inflammation; ketone body; lactate; lipolysis; therapy of diseases

Indexed keywords

CARBOXYLIC ACID; HYDROXY CARBOXYLIC ACID RECEPTOR; HYDROXYACID; UNCLASSIFIED DRUG; 3 HYDROXYBUTYRIC ACID; G PROTEIN COUPLED RECEPTOR; KETONE; LACTIC ACID;

ATHEROSCLEROSIS; ENERGY METABOLISM; GENE FUNCTION; HIGH FIBER DIET; HUMAN; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; WHITE ADIPOSE TISSUE; ANIMAL; INFLAMMATION; LIPOLYSIS; METABOLISM; PHYSIOLOGY;

3-HYDROXYBUTYRIC ACID; ANIMALS; CARBOXYLIC ACIDS; HUMANS; INFLAMMATION; KETONES; LACTIC ACID; LIPOLYSIS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 85009193567     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2016.11.007     Document Type: Review

References (99)

1. 1 Hong, C., Tontonoz, P., Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr. Opin. Genet. Dev. 18 (2008), 461–467.
2. 2 Kalaany, N.Y., Mangelsdorf, D.J., LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu. Rev. Physiol. 68 (2006), 159–191.
3. 3 Blad, C.C., et al. G protein-coupled receptors for energy metabolites as new therapeutic targets. Nat. Rev. Drug Discov. 11 (2012), 603–619.
4. 4 Offermanns, S., et al. International Union of Basic and Clinical Pharmacology. LXXXII: nomenclature and classification of hydroxy-carboxylic acid receptors (GPR81, GPR109A, and GPR109B). Pharmacol. Rev. 63 (2011), 269–290.
5. 5 Tang, H., et al. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem. Biophys. Res. Commun. 375 (2008), 562–565.
6. 6 Hanson, J., et al. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J. Clin. Invest. 120 (2010), 2910–2919.
7. 7 Shen, H.C., Colletti, S.L., Novel patent publications on high-affinity nicotinic acid receptor agonists. Expert Opin. Ther. Pat. 19 (2009), 957–967.
8. 8 Kuei, C., et al. Study of GPR81, the lactate receptor, from distant species identifies residues and motifs critical for GPR81 functions. Mol. Pharmacol. 80 (2011), 848–858.
9. 9 Zellner, C., et al. Variations in human HM74 (GPR109B) and HM74A (GPR109A) niacin receptors. Hum. Mutat. 25 (2005), 18–21.
10. 10 Cai, T.Q., et al. Role of GPR81 in lactate-mediated reduction of adipose lipolysis. Biochem. Biophys. Res. Commun. 377 (2008), 987–991.
11. 11 Liu, C., et al. Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor, GPR81. J. Biol. Chem. 284 (2009), 2811–2822.
12. 12 Ahmed, K., et al. Deorphanization of GPR109B as a receptor for the beta-oxidation intermediate 3-OH-octanoic acid and its role in the regulation of lipolysis. J. Biol. Chem. 284 (2009), 21928–21933.
13. 13 Ahmed, K., et al. An autocrine lactate loop mediates insulin-dependent inhibition of lipolysis through GPR81. Cell Metab. 11 (2010), 311–319.
14. 14 Tunaru, S., et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med. 9 (2003), 352–355.
15. 15 Soga, T., et al. Molecular identification of nicotinic acid receptor. Biochem. Biophys. Res. Commun. 303 (2003), 364–369.
16. 16 Wise, A., et al. Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem. 278 (2003), 9869–9874.
17. 17 Ge, H., et al. Elucidation of signaling and functional activities of an orphan GPCR, GPR81. J. Lipid Res. 49 (2008), 797–803.
18. 18 Jeninga, E.H., et al. Peroxisome proliferator-activated receptor gamma regulates expression of the anti-lipolytic G-protein-coupled receptor 81 (GPR81/Gpr81). J. Biol. Chem. 284 (2009), 26385–26393.
19. 19 Regard, J.B., et al. Anatomical profiling of G protein-coupled receptor expression. Cell 135 (2008), 561–571.
20. 20 Schaub, A., et al. PUMA-G, an IFN-gamma-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily. Eur. J. Immunol. 31 (2001), 3714–3725.
21. 21 Benyo, Z., et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J. Clin. Invest. 115 (2005), 3634–3640.
22. 22 Kostylina, G., et al. Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A). Cell Death Differ. 15 (2008), 134–142.
23. 2 in response to nicotinic acid. J. Invest. Dermatol. 126 (2006), 2637–2646.
24. 24 Thangaraju, M., et al. GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res. 69 (2009), 2826–2832.
25. 25 Martin, P.M., et al. Expression and localization of GPR109A (PUMA-G/HM74A) mRNA and protein in mammalian retinal pigment epithelium. Mol. Vis. 15 (2009), 362–372.
26. 26 Cresci, G.A., et al. Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8. J. Gastrointest. Surg. 14 (2010), 449–461.
27. 27 Soga, T., et al. Molecular cloning and characterization of prokineticin receptors. Biochim. Biophys. Acta 1579 (2002), 173–179.
28. 28 Irukayama-Tomobe, Y., et al. Aromatic D-amino acids act as chemoattractant factors for human leukocytes through a G protein-coupled receptor, GPR109B. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 3930–3934.
29. 29 Nomura, H., et al. Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors. Int. Immunol. 5 (1993), 1239–1249.
30. 30 Yousefi, S., et al. cDNA representational difference analysis of human neutrophils stimulated by GM-CSF. Biochem. Biophys. Res. Commun. 277 (2000), 401–409.
31. 31 Wanders, D., et al. Effects of high fat diet on GPR109A and GPR81 gene expression. Biochem. Biophys. Res. Commun. 425 (2012), 278–283.
32. 32 Feingold, K.R., et al. Inflammation inhibits GPR81 expression in adipose tissue. Inflamm. Res. 60 (2011), 991–995.
33. 33 Osnes, J.B., Hermansen, L., Acid-base balance after maximal exercise of short duration. J. Appl. Physiol. 32 (1972), 59–63.
34. 34 DiGirolamo, M., et al. Lactate production in adipose tissue: a regulated function with extra-adipose implications. FASEB J. 6 (1992), 2405–2412.
35. 35 Qvisth, V., et al. Lactate release from adipose tissue and skeletal muscle in vivo: defective insulin regulation in insulin-resistant obese women. Am. J. Physiol. Endocrinol. Metab. 292 (2007), E709–E714.
36. 36 Jansson, P.A., et al. Lactate release from the subcutaneous tissue in lean and obese men. J. Clin. Invest. 93 (1994), 240–246.
37. 37 Arner, P., Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Pract. Res. Clin. Endocrinol. Metab. 19 (2005), 471–482.
38. 38 Arner, P., Langin, D., Lipolysis in lipid turnover, cancer cachexia, and obesity-induced insulin resistance. Trends Endocrinol. Metab. 25 (2014), 255–262.
39. 39 Harms, M., Seale, P., Brown and beige fat: development, function and therapeutic potential. Nat. Med. 19 (2013), 1252–1263.
40. 40 Owen, O.E., et al. Liver and kidney metabolism during prolonged starvation. J. Clin. Invest. 48 (1969), 574–583.
41. 41 Senior, B., Loridan, L., Direct regulatory effect of ketones on lipolysis and on glucose concentrations in man. Nature 219 (1968), 83–84.
42. 42 Taggart, A.K., et al. (D)-β-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J. Biol. Chem. 280 (2005), 26649–26652.
43. 43 Costa, C.G., et al. Simultaneous analysis of plasma free fatty acids and their 3-hydroxy analogs in fatty acid beta-oxidation disorders. Clin. Chem. 44 (1998), 463–471.
44. 44 Carlson, L.A., Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med. 258 (2005), 94–114.
45. 45 Hernandez, M., et al. Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice. Biochem. Biophys. Res. Commun. 355 (2007), 1075–1080.
46. 46 van der Hoorn, J.W., et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler. Thromb. Vasc. Biol. 28 (2008), 2016–2022.
47. 47 Lauring, B., et al. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci. Transl. Med., 4, 2012, 148ra115.
48. 48 Kingwell, B.A., et al. HDL-targeted therapies: progress, failures and future. Nat. Rev. Drug Discov. 13 (2014), 445–464.
49. 49 Morigny, P., et al. Adipocyte lipolysis and insulin resistance. Biochimie 125 (2016), 259–266.
50. 50 Girousse, A., et al. Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass. PLoS Biol., 11, 2013, e1001485.
51. 51 Dobbins, R., et al. GSK256073 acutely regulates NEFA levels via HCA2 agonism but does not achieve durable glycaemic control in type 2 diabetes. A randomised trial. Eur. J. Pharmacol. 755 (2015), 95–101.
52. 52 Chen, L., et al. Niacin-induced hyperglycemia is partially mediated via niacin receptor GPR109a in pancreatic islets. Mol. Cell. Endocrinol. 404 (2015), 56–66.
53. 53 Wang, N., et al. Niacin receptor GPR109A inhibits insulin secretion and is down-regulated in type 2 diabetic islet beta-cells. Gen. Comp. Endocrinol. 237 (2016), 98–108.
54. 54 Lukasova, M., et al. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J. Clin. Invest. 121 (2011), 1163–1173.
55. 55 Wu, B.J., et al. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler. Thromb. Vasc. Biol. 30 (2010), 968–975.
56. 56 Zandi-Nejad, K., et al. The role of HCA2 (GPR109A) in regulating macrophage function. FASEB J. 27 (2013), 4366–4374.
57. 57 Plaisance, E.P., et al. Niacin stimulates adiponectin secretion through the GPR109A receptor. Am. J. Physiol. Endocrinol. Metab. 296 (2009), E549–E558.
58. 58 Graff, E.C., et al. Anti-inflammatory effects of the hydroxycarboxylic acid receptor 2. Metabolism 65 (2016), 102–113.
59. 59 Boden, W.E., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365 (2011), 2255–2267.
60. 60 Hps2 Thrive Collaborative Group, HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 34 (2013), 1279–1291.
61. 61 Dunbar, R.L., Goel, H., Niacin alternatives for dyslipidemia: fool's gold or gold mine? Part I: alternative niacin regimens. Curr. Atheroscler. Rep., 18, 2016, 11.
62. 62 Goel, H., Dunbar, R.L., Niacin alternatives for dyslipidemia: fool's gold or gold mine? Part II: novel niacin mimetics. Curr. Atheroscler. Rep., 18, 2016, 17.
63. 2 ameliorates neuroinflammation. Trends Mol. Med. 21 (2015), 245–255.
64. 64 Kappos, L., et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372 (2008), 1463–1472.
65. 65 Chen, H., et al. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. J. Clin. Invest. 124 (2014), 2188–2192.
66. 66 Parodi, B., et al. Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathol. 130 (2015), 279–295.
67. 67 Rahman, M., et al. The beta-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages. Nat. Commun., 5, 2014, 3944.
68. 68 Atwan, A., et al. Oral fumaric acid esters for psoriasis. Cochrane Database Syst. Rev., 2015, CD010497.
69. 69 Mrowietz, U., Asadullah, K., Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol. Med. 11 (2005), 43–48.
70. 70 Koh, A., et al. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell 165 (2016), 1332–1345.
71. 71 Leonel, A.J., Alvarez-Leite, J.I., Butyrate: implications for intestinal function. Curr. Opin. Clin. Nutr. Metab. Care 15 (2012), 474–479.
72. 72 Singh, N., et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 40 (2014), 128–139.
73. 73 Macia, L., et al. Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat. Commun., 6, 2015, 6734.
74. 74 Tan, J., et al. Dietary fiber and bacterial SCFA enhance oral tolerance and protect against food allergy through diverse cellular pathways. Cell Rep. 15 (2016), 2809–2824.
75. 75 Chang, P.V., et al. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 2247–2252.
76. 76 Schilderink, R., et al. The SCFA butyrate stimulates the epithelial production of retinoic acid via inhibition of epithelial HDAC. Am. J. Physiol. Gastrointest. Liver Physiol. 310 (2016), G1138–G1146.
77. 77 Staubert, C., et al. Hydroxycarboxylic acid receptors are essential for breast cancer cells to control their lipid/fatty acid metabolism. Oncotarget 6 (2015), 19706–19720.
78. 78 Wagner, W., et al. L- and D-lactate enhance DNA repair and modulate the resistance of cervical carcinoma cells to anticancer drugs via histone deacetylase inhibition and hydroxycarboxylic acid receptor 1 activation. Cell Commun. Signal., 13, 2015, 36.
79. 79 Roland, C.L., et al. Cell surface lactate receptor GPR81 is crucial for cancer cell survival. Cancer Res. 74 (2014), 5301–5310.
80. 80 Walenta, S., et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 60 (2000), 916–921.
81. 81 Menendez, J.A., Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives. Biochim. Biophys. Acta 1801 (2010), 381–391.
82. 82 Lee, Y.J., et al. G-protein-coupled receptor 81 promotes a malignant phenotype in breast cancer through angiogenic factor secretion. Oncotarget., 2016 Published online September 27, 2016 http://dx.doi.org/10.18632/oncotarget.12286.
83. 83 Elangovan, S., et al. The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival. Cancer Res. 74 (2014), 1166–1178.
84. 84 Singh, V., et al. Mycobacterium tuberculosis-driven targeted recalibration of macrophage lipid homeostasis promotes the foamy phenotype. Cell Host Microbe 12 (2012), 669–681.
85. 85 Kumar, D., et al. Genome-wide analysis of the host intracellular network that regulates survival of Mycobacterium tuberculosis. Cell 140 (2010), 731–743.
86. 86 Singh, V., et al. M. tuberculosis secretory protein ESAT-6 induces metabolic flux perturbations to drive foamy macrophage differentiation. Sci. Rep., 5, 2015, 12906.
87. 87 Agrawal, N., et al. Dissecting host factors that regulate the early stages of tuberculosis infection. Tuberculosis (Edinb) 100 (2016), 102–113.
88. 88 Rostami Yazdi, M., Mrowietz, U., Fumaric acid esters. Clin. Dermatol. 26 (2008), 522–526.
89. 2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 6682–6687.
90. 90 Yadav, R., et al. Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety. Expert Opin. Pharmacother. 13 (2012), 1345–1362.
91. 91 Walters, R.W., et al. beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J. Clin. Invest. 119 (2009), 1312–1321.
92. 92 Liu, C., et al. 3,5-Dihydroxybenzoic acid, a specific agonist for HCA1, inhibits lipolysis in adipocytes. J. Pharmacol. Exp. Ther. 341 (2012), 794–801.
93. 93 Engelstoft, M.S., et al. Seven transmembrane G protein-coupled receptor repertoire of gastric ghrelin cells. Mol. Metab. 2 (2013), 376–392.
94. 94 Palani, A., et al. Discovery of SCH 900271, a potent nicotinic acid receptor agonist for the treatment of dyslipidemia. ACS Med. Chem. Lett. 3 (2012), 63–68.
95. 95 Boatman, P.D., et al. (1aR,5aR)1a, 3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans. J. Med. Chem. 55 (2012), 3644–3666.
96. 96 Shen, H.C., et al. Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate. J. Med. Chem. 53 (2010), 2666–2670.
97. 97 Sprecher, D., et al. Discovery and characterization of GSK256073, a non-flushing hydroxy-carboxylic acid receptor 2 (HCA2) agonist. Eur. J. Pharmacol. 756 (2015), 1–7.
98. 98 Semple, G., et al. 1-Alkyl-benzotriazole-5-carboxylic acids are highly selective agonists of the human orphan G-protein-coupled receptor GPR109b. J. Med. Chem. 49 (2006), 1227–1230.
99. 99 Skinner, P.J., et al. 5-N,N-disubstituted 5-aminopyrazole-3-carboxylic acids are highly potent agonists of GPR109b. Bioorg. Med. Chem. Lett. 19 (2009), 4207–4209.